New hope for rare skin cancer: targeted antibody tested in china

NCT ID NCT06285370

Ongoing Disease control Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph nodes, and blood. Researchers will measure how many patients achieve a complete or partial response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mogamulizumab (a monoclonal antibody given by IV infusion)
What this could lead to: If successful, this could provide a new treatment option for Chinese patients with these rare skin lymphomas who have not responded to prior therapies.
What could go wrong: This is a small, single-arm study with only 23 participants, so results may not apply broadly. The drug may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA

Contacts and locations

Locations

First Affiliated Hospital of Zhengzhou University

Henan, Zhengzhou, 450052, China
Peking University First Hospital, Department of Dermatology and Venereology

Beijing, Beijing Municipality, 100034, China
Sun Yat-sen University Cancer Center, Department of Medical Oncology

Guangzhou, Guangdong, 510060, China
The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010000, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110002, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610044, China
ZheJiang Cancer Hospital

Hangzhou, Zhejiang, 310005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.